Heterosexual Anal Sex Activity in the Year After an STD Clinic Visit

Tian, Lin; Peterman, Thomas A.; Tao, Guoyu; Brooks, Lesley C.; Metcalf, Carol; Malotte, C. Kevin; Paul, Sindy M.; Douglas, John M.

doi:10.1097/olq.0b013e318181294b

Cited by 63 publications

(62 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, substance users who engage in anal intercourse are more likely to have contracted STI in general, although not HIV in particular. Heterosexual anal sex is prevalent among STI clinic patients, with more than one in five patients reporting anal sex in the previous 3 months, and 39% reporting anal intercourse in the past year 7 8. These findings are consistent with other studies that show a significant and potentially growing number of heterosexual individuals engaging in anal sex practices 9.…”

supporting

confidence: 88%

Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa

Kalichman

Simbayi²,

Cain³

et al. 2009

Sexually Transmitted Infections

108

View full text Add to dashboard Cite

show abstract

supporting

confidence: 88%

Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa

Kalichman

Simbayi²,

Cain³

et al. 2009

Sexually Transmitted Infections

108

View full text Add to dashboard Cite

show abstract

“…However, recent efforts have expanded to optimize products to safely prevent HIV transmission during receptive anal intercourse as well. While these new products are directed at reducing the incidence of HIV among men who have sex with men (MSM), it has also been acknowledged that heterosexual anal intercourse may be underreported due to social taboos and other factors (27)(28)(29). This issue has shifted the paradigm of microbicide development toward a new generation of dual-compartment microbicides that are safe for both vaginal and rectal use (30,31).…”

Section: Discussionmentioning

confidence: 99%

Broadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex Vivo

Scott

Park

Dezzutti

2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

cBroadly neutralizing monoclonal antibodies (nAbs) specific for HIV are being investigated for use in HIV prevention. Due to their ability to inhibit HIV attachment to and entry into target cells, nAbs may be suitable for use as topical HIV microbicides. As such, they would present an alternative intervention for individuals who may not benefit from using antiretroviral-based products for HIV prevention. We theorize that nAbs can inhibit viral transmission through mucosal tissue, thus reducing the incidence of HIV infection. The efficacy of the PG9, PG16, VRC01, and 4E10 antibodies was evaluated in an ex vivo human model of mucosal HIV transmission. nAbs reduced HIV transmission, causing 1.5-to 2-log 10 reductions in HIV replication in ectocervical tissues and Ϸ3-log 10 reductions in HIV replication in colonic tissues over 21 days. These antibodies demonstrated greater potency in colonic tissues, with a 50-fold higher dose being required to reduce transmission in ectocervical tissues. Importantly, nAbs retained their potency and reduced viral transmission in the presence of whole semen. No changes in tissue viability or immune activation were observed in colonic or ectocervical tissue after nAb exposure. Our data suggest that topically applied nAbs are safe and effective against HIV infection of mucosal tissue and support further development of nAbs as a topical microbicide that could be used for anal as well as vaginal protection.

show abstract

“…[27], [28] A result of the under-recognition of the prevalence of anal intercourse is that HIV prevention research and interventions for women have tended to focus almost exclusively on vaginal intercourse. Women are less likely to report condom use during anal intercourse than during vaginal intercourse[24], [25] and some women erroneously perceive that transmission risk is lower for anal than for vaginal sex.…”

Section: Women and Anal Intercoursementioning

confidence: 99%

Preventing HIV Infection in Women

Adimora

Ramirez

Auerbach

et al. 2013

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Although the number of new infections has declined recently, women still constitute almost half of the world's 34 million people with HIV infection, and HIV remains the leading cause of death among women of reproductive age. Prevention research has made considerable progress during the past few years in addressing the biological, behavioral and social factors that influence women's vulnerability to HIV infection. Nevertheless, substantial work still must be done in order to implement scientific advancements and to resolve the many questions that remain. This article highlights some of the recent advances and persistent gaps in HIV prevention research for women and outlines key research and policy priorities.

show abstract

Heterosexual Anal Sex Activity in the Year After an STD Clinic Visit

Cited by 63 publications

References 28 publications

Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa

Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa

Broadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex Vivo

Preventing HIV Infection in Women

Contact Info

Product

Resources

About